Corcept Therapeutics(CORT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CORT Corcept Therapeutics

Market Closed 03-28 16:00:00 EDT

54.63

-2.05

-3.62%

盘后58.63

+4.00+7.32%

19:45 EDT

High57.51	Low53.79	Vol653.63K
Open56.82	D1 Closing56.68	Amplitude6.56%
Mkt Cap5.76B	Tradable Cap4.75B	Total Shares105.50M
T/O35.75M	T/O Rate0.75%	Tradable Shares86.91M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"CORT","market":"US","secType":"STK","nameCN":"Corcept Therapeutics","latestPrice":54.63,"timestamp":1743192000000,"preClose":56.68,"halted":0,"volume":653627,"hourTrading":{"tag":"盘后","latestPrice":58.63,"preClose":54.63,"latestTime":"19:45 EDT","volume":20644,"amount":1128220.6334,"timestamp":1743205555865},"delay":0,"floatShares":86913769,"shares":105503432,"eps":1.23,"marketStatus":"Market Closed","change":-2.05,"latestTime":"03-28 16:00:00 EDT","open":56.82,"high":57.51,"low":53.79,"amount":35752634.117291,"amplitude":0.065632,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.23,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1743408000000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1081915200000,"exchange":"NASDAQ","adjPreClose":56.68,"preHourTrading":{"tag":"盘前","latestPrice":56.95,"preClose":56.68,"latestTime":"09:29 EDT","volume":186,"amount":10601.92932,"timestamp":1743168599999},"postHourTrading":{"tag":"盘后","latestPrice":58.63,"preClose":54.63,"latestTime":"19:45 EDT","volume":20644,"amount":1128220.6334,"timestamp":1743205555865},"volumeRatio":0.7247970700584268,"impliedVol":0.6099,"impliedVolPercentile":0.392},"requestUrl":"/m/hq/s/CORT","defaultTab":"news","newsList":[{"id":"2523685959","title":"Why Is Corcept (CORT) Down 5.3% Since Last Earnings Report?","url":"https://stock-news.laohu8.com/highlight/detail?id=2523685959","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523685959?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 23:30","pubTimestamp":1743175842,"startTime":"0","endTime":"0","summary":"It has been about a month since the last earnings report for Corcept Therapeutics . Shares have lost about 5.3% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Corcept due for a breakout?Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.It turns out, fresh estimates have trended downward during the past month.The consensus estimate has shifted -55.2% due to these changes.Corcept is part of the Zacks Medical - Drugs industry. Over the past month, Summit Therapeutics PLC , a stock from the same industry, has gained 11.4%. The company reported its results for the quarter ended December 2024 more than a month ago.Summit Therapeutics PLC  : Free Stock Analysis Report. This article originally published on Zacks Investment Research .","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-corcept-cort-down-5-153042433.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SMMT","CORT"],"gpt_icon":0},{"id":"2523075615","title":"Kodiak Q4 Loss Narrower Than Expected, Pipeline Development in Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2523075615","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523075615?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 21:45","pubTimestamp":1743169500,"startTime":"0","endTime":"0","summary":"Kodiak SciencesKOD reported a loss of 84 cents per share in the fourth quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 90 cents. The company had incurred a loss of $1.13 per share in the year-ago quarter.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.The company currently does not have any approved products in its portfolio. As a result, it has yet to generate revenues.Research and development expenses were $31.8 million in the reported quarter, down 32% year over year. The decrease was mainly due to reduced manufacturing activities and forfeitures of equity awards, partially offset by clinical activities from active studies.General and administrative expenses were $14.4 million, down 14% year over year, primarily due to lower non-cash stock-based compensation expenses.Kodiak is also enrolling patients in the phase Ib APEX study, which will evaluate its third investigational candidate, KSI-101, in two new cohorts — cohort 1 in patients w","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kodiak-q4-loss-narrower-expected-134500496.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0004445239.USD","CORT","LU0979878070.USD","LU0823421416.USD","BK4505","BK4007","KOD","BK4532","BAYRY","LU0823434740.USD","LU2250418816.HKD","BK4585","LU2360106780.USD","LU2458330169.SGD","LU1988902786.USD","LU0823434583.USD","LU2458330243.SGD","BK4529","LU1559883803.SGD","LU1880398554.USD","BK4554","IE00B5949003.HKD","LU1242518857.USD","BK4534","LU1951198990.SGD","LU1064131342.USD","LU0823421333.USD","LU1803068979.SGD","DVAX","LU2054465674.USD","BK4139","LU1951200564.SGD","LU0642271901.SGD","BK4573","LU1880398471.USD","BK4141","BK4605","LU1852331112.SGD","LU0127658192.USD","LU1303367103.USD","BK4588","BK4543","LU1989764664.SGD","LU2098885051.SGD","BK4512","LU0081259029.USD","LU0082616367.USD","IE0009356076.USD","IE00BMPRXR70.SGD"],"gpt_icon":1},{"id":"2522003463","title":"SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2522003463","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522003463?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 20:46","pubTimestamp":1743079560,"startTime":"0","endTime":"0","summary":"Shares of Soleno TherapeuticsSLNO have rallied 37% in the premarket hours today following the FDA approval of Vykat XR extended-release tablets for treating hyperphagia in adults and children aged four years and older with Prader-Willi syndrome . The company expects to launch the drug in the United States in April 2025.Soleno’s Vykat XR, previously referred to as DCCR, is an innovative, once-daily, proprietary extended-release dosage form that contains diazoxide choline, the crystalline salt form of diazoxide. Although not approved for treating PWS, the parent molecule, diazoxide, treats a few rare diseases in neonates, infants, children and adults.Per the PWS Association USA, approximately one in every 15,000 newborns suffers from this rare genetic disorder. The most common symptom of PWS is hyperphagia, an abnormally increased appetite for food, often leading to excessive eating, which takes a serious toll on the quality of life of patients suffering from it. In the long term, hyperp","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/slno-stock-rallies-fda-approval-124600150.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2065171402.SGD","LU2065171311.SGD","LU0566484027.USD","ACAD","BK4007","BAYRY","BK4532","CORT","LU2065169927.USD","SLNO","BK4139","LU2065170008.USD","PWS","LU1559883803.SGD"],"gpt_icon":0},{"id":"2522357131","title":"3 Reasons to Sell CORT and 1 Stock to Buy Instead","url":"https://stock-news.laohu8.com/highlight/detail?id=2522357131","media":"StockStory","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522357131?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 05:41","pubTimestamp":1743025276,"startTime":"0","endTime":"0","summary":"Corcept currently trades at $58.76 and has been a dream stock for shareholders. It’s returned 434% since March 2020, blowing past the S&P 500’s 117% gain. The company has also beaten the index over the past six months as its stock price is up 35.8%.Is now the time to buy Corcept, or should you be careful about including it in your portfolio?See what our analysts have to say in our full research report, it’s free.We’re glad investors have benefited from the price increase, but we're cautious about Corcept. Here are three reasons why you should be careful with CORT and a stock we'd rather own.As you can see below, Corcept’s margin dropped by 13.6 percentage points over the last five years. It may have ticked higher more recently, but shareholders are likely hoping for its margin to at least revert to its historical level. If the longer-term trend returns, it could signal it is in the middle of an investm","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-reasons-sell-cort-1-214116581.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CORT","BK4007","LU0566484027.USD","LU1559883803.SGD","BK4532"],"gpt_icon":0},{"id":"2521361282","title":"Is Corcept Therapeutics (CORT) Stock Outpacing Its Medical Peers This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=2521361282","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521361282?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 21:40","pubTimestamp":1742564408,"startTime":"0","endTime":"0","summary":"For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Corcept Therapeutics  been one of those stocks this year?Let's take a closer look at the stock's year-to-date performance to find out.Corcept Therapeutics is one of 1012 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.Based on the latest available data, CORT has gained about 14.3% so far this year. Meanwhile, stocks in the Medical group have gained about 4.9% on average. This means that Corcept Therapeutics is performing better than its sector in terms of year-to-date returns.Another stock in the Medical sector, ANI Pharmaceuticals , has outperformed the sector so far this year. The stock's year-to-date retur","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/corcept-therapeutics-cort-stock-outpacing-134008027.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","LU0566484027.USD","CORT","LU1559883803.SGD","ANIP","BK4532"],"gpt_icon":0},{"id":"2520213306","title":"3 Growth Stocks in Hot Water","url":"https://stock-news.laohu8.com/highlight/detail?id=2520213306","media":"StockStory","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520213306?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 21:03","pubTimestamp":1742389381,"startTime":"0","endTime":"0","summary":"Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who lost money in tech stocks during 2022.Deciphering which businesses can sustain their high growth rates is a challenge for even the most seasoned professionals, which is why we started StockStory. That said, here are three growth stocks climbing an uphill battle and some other opportunities you should consider instead.Starting in the seamless tube industry, Quanex  manufactures building products like window, door, kitchen, and bath cabinet components.Costs have risen faster than its revenue over the last five years, causing its operating margin to decline by 4.6 percentage points. Incremental sales over the last two years were much less profitable as its earnings per share fell by 6.9% annually while its revenue grew. Capital intensity has ramped up over the last five years as its free cash f","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-growth-stocks-hot-water-130301825.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CORT","SEM","BK4007","BK4532","LU1559883803.SGD","BK4086","LU0566484027.USD","LU2065732104.USD","BK4185","NX"],"gpt_icon":0},{"id":"2520576748","title":"AZN to Acquire EsoBiotec for $1B to Develop In Vivo Cell Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2520576748","media":"Zacks","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520576748?lang=en_us&edition=full_marsco","pubTime":"2025-03-17 21:38","pubTimestamp":1742218680,"startTime":"0","endTime":"0","summary":"AstraZenecaAZN announced that it has entered into a definitive agreement to acquire EsoBiotec for developing in vivo cell therapies for multiple cancer indications or immune-mediated diseases. EsoBiotec is a biotechnology company specializing in “in vivo” cell therapies with promising early clinical results.The acquisition will integrate EsoBiotec’s proprietary ENaBL platform, which empowers the immune system’s ability to target cancers, into AstraZeneca’s portfolio. This technology has the potential to expand patient access to transformative cell therapy treatments, delivering results in minutes instead of the current weeks-long process. The deal will allow EsoBiotec to leverage AZN’s vast resources and expertise in cell therapies to accelerate the development of their in vivo platform which has a novel delivery technology that is expected to have broad therapeutic applicability.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/azn-acquire-esobiotec-1b-develop-133800753.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2417539215.USD","BK4139","LU1066053197.SGD","BMRN","IE00B3T34201.USD","BK4578","LU2236285917.USD","IE00BSNM7G36.USD","LU2456880835.USD","LU0320765992.SGD","IE00BZ1G4Q59.USD","BK4568","LU1430594728.SGD","LU1571399168.USD","BK4585","LU2468319806.SGD","LU1066051498.USD","BK4550","LU0109394709.USD","BK4583","IE00B7SZLL34.SGD","AZN","BK4588","BK4566","LU1839511570.USD","CORT","IE00B19Z3581.USD","LU0234570918.USD","BK4007","LU2462157665.USD","BK4532","IE00B19Z3B42.SGD","IE00BKVL7J92.USD","LU0566484027.USD","IE0002270589.USD","LU2087621335.USD","LU0289739699.SGD","LU2089984988.USD","LU1559883803.SGD","GILD","LU1585245621.USD","LU1829250122.USD","LU0889565916.HKD","LU0058720904.USD"],"gpt_icon":0},{"id":"2518477984","title":"NVO Stock Down 9% as CagriSema Misses Target in Second Obesity Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2518477984","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518477984?lang=en_us&edition=full_marsco","pubTime":"2025-03-12 01:51","pubTimestamp":1741715460,"startTime":"0","endTime":"0","summary":"Novo Nordisk NVO has achieved the primary endpoint in the second late-stage study evaluating its next-gen subcutaneous obesity treatment candidate, CagriSema, in patients with obesity and type 2 diabetes  and a mean baseline body weight of 102 kg. The results showed that treatment with the candidate led to a statistically significant and superior weight loss at week 68compared with placebo.NVO’s CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg and Wegovy. The two molecules promote weight loss by suppressing hunger, enhancing feelings of fullness and helping individuals consume fewer calories.The phase III REDEFINE 2 study followed a flexible protocol, enabling patients to adjust their dosing throughout the study. After 68 weeks, 61.9% of those treated with CagriSema reached the highest dose.Novo Nordisk plans to submit a regulatory application seeking the first approval for CagriSema for the obesity indication in the first quarter of 2026. Det","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nvo-stock-down-9-cagrisema-175100065.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4583","LU0234570918.USD","IE00B19Z3581.USD","LU0566484027.USD","LU0154236417.USD","BK4007","GILD","IE0002270589.USD","IE00BKVL7J92.USD","LU0058720904.USD","LU2087621335.USD","LU1585245621.USD","IE00BSNM7G36.USD","BK4566","LU1066053197.SGD","LU0889565916.HKD","CORT","BK4532","IE00B19Z3B42.SGD","LU2468319806.SGD","IE00BZ1G4Q59.USD","LU1093756168.USD","BK4568","LU0320765992.SGD","LU0289739699.SGD","LU1093756325.SGD","IE00B3T34201.USD","IE00B7SZLL34.SGD","BK4550","BMRN","LU1559883803.SGD","LU0109394709.USD","LU2089984988.USD","BK4585","BK4588","LU1839511570.USD","BK4578","LU1571399168.USD","BK4599","NVO","LU1430594728.SGD","LU1066051498.USD","BK4139"],"gpt_icon":1},{"id":"2518072238","title":"KOD Completes Enrollment in Phase III Study for Eye Disease Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2518072238","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518072238?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 22:39","pubTimestamp":1741703940,"startTime":"0","endTime":"0","summary":"Kodiak SciencesKOD announced that it has completed enrollment in a late-stage study of tarcocimab tedromer in patients with diabetic retinopathy . Per KOD, more than 250 patients have been enrolled in the phase III GLOW2 study, surpassing the initial enrollment target. With a 48-week treatment duration, all patients are expected to complete their primary endpoint visits by the end of January 2026. The top-line clinical data is anticipated to be announced in the first quarter of 2026.In late 2023, Kodiak rebooted the development program of tarcocimab following positive phase III results from the GLOW1 study, which evaluated the treatment in patients with moderately severe to severe non-proliferative diabetic retinopathy. Leveraging the GLOW1 study's success, Kodiak initiated the GLOW2 study to further investigate tarcocimab for DR and began dosing patients in May 2024. Enrolled DR patients will receive tarcocimab on extended dosing intervals, including six-month dosing for all patients.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kod-completes-enrollment-phase-iii-143900570.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1839511570.USD","LU1559883803.SGD","LU0082616367.USD","BK4573","LU2360106780.USD","BK4141","LU0109394709.USD","LU2089984988.USD","LU1951200564.SGD","LU0056508442.USD","LU2054465674.USD","GILD","BK4585","LU0642271901.SGD","IE00B3T34201.USD","LU1803068979.SGD","LU1880398554.USD","KOD","LU0127658192.USD","LU2468319806.SGD","LU1923623000.USD","BK4583","BK4575","LU0719512351.SGD","LU0889565916.HKD","LU0320765992.SGD","BMRN","IE00B19Z3581.USD","LU1951198990.SGD","LU1316542783.SGD","BK4554","LU0390134368.USD","BK4612","IE00B19Z3B42.SGD","III","LU0823434583.USD","LU2458330243.SGD","LU2458330169.SGD","LU2250418816.HKD","LU0889565833.HKD","LU1066051498.USD","CORT","BK4550","LU1988902786.USD","BK4614","BK4578","IE00BSNM7G36.USD","LU2098885051.SGD","IE0009356076.USD"],"gpt_icon":1},{"id":"2518434747","title":"Top Growth Companies With Significant Insider Ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2518434747","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518434747?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 19:05","pubTimestamp":1741691129,"startTime":"0","endTime":"0","summary":"As the U.S. stock market grapples with heightened volatility due to tariff concerns and recession fears, investors are increasingly seeking stability amidst uncertainty. In such an environment, growth companies with significant insider ownership can offer a unique appeal, as high insider stakes often indicate confidence in the company's long-term potential despite broader market turbulence.Top 10 Growth Companies With High Insider Ownership In The United States. Click here to see the full list of 205 stocks from our Fast Growing US Companies With High Insider Ownership screener.Overview: Corcept Therapeutics Incorporated focuses on discovering and developing medications for severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States, with a market cap of approximately $5.95 billion.Operations: The company's revenue primarily comes from the discovery, development, and commercialization of pharmaceutical products, amounting to $675.04 million.Operations: Zs","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/top-growth-companies-significant-insider-110529723.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","TBBB","BK4097","BK4585","BK4196","LU1923622291.USD","BK4532","BK4113","ZS","BK4007","BK4560","LU2125909916.SGD","LU2125909759.SGD","CORT","LU0390134368.USD","LU1559883803.SGD","KULR","LU0566484027.USD","LU2286300806.USD"],"gpt_icon":1},{"id":"2518768142","title":"BRIEF-Corcept Therapeutics launches study on link between high cortisol and resistant hypertension","url":"https://stock-news.laohu8.com/highlight/detail?id=2518768142","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518768142?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 22:54","pubTimestamp":1741618481,"startTime":"0","endTime":"0","summary":"BRIEF-Corcept Therapeutics launches study on link between high cortisol and resistant hypertensionMarch 10  - Corcept Therapeutics Inc CORT.O:CORCEPT THERAPEUTICS INITIATES MOMENTUM TRIAL TO DETERMINE PREVALENCE OF HYPERCORTISOLISM IN PATIENTS WITH RESISTANT HYPERTENSIONSource text: nBw9cq9NLaFurther company coverage: CORT.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nFWN3PT0PJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0566484027.USD","CORT","BK4532","BK4007","LU1559883803.SGD"],"gpt_icon":0},{"id":"2518565270","title":"INCY Opzelura Shows Superior Efficacy in 2 Prurigo Nodularis Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2518565270","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518565270?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 22:52","pubTimestamp":1741618320,"startTime":"0","endTime":"0","summary":"IncyteINCY announced positive results from two late-stage studies evaluating the safety and efficacy of its twice-daily ruxolitinib cream 1.5% in adults with prurigo nodularis . The data readout from both studies was recently presented at the 2025American Academy of Dermatology Annual Meeting.PN is a chronic inflammatory skin condition causing intense itching and thickened red nodules, primarily on the arms, legs, and trunk. Affecting around 200,000 people in the United States, it is most common in individuals aged 40-69. Persistent scratching leads to nodules, significantly impacting sleep and overall quality of life.Please note that ruxolitinib cream 1.5%, a topical JAK1/2 inhibitor, is currently approved in the United States under the brand name Opzelura for treating nonsegmental vitiligo in patients aged 12 and older. It is also approved for short-term and non-continuous chronictreatment of mild to moderate atopic dermatitis in non-immunocompromised patients of the same age group w","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/incy-opzelura-shows-superior-efficacy-145200413.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B7SZLL34.SGD","BK4550","IE00B19Z3581.USD","IE0002270589.USD","BK4007","BK4532","LU1571399168.USD","INCY","GILD","LU0109394709.USD","BK4566","PN","LU0058720904.USD","LU0889565916.HKD","LU0289739699.SGD","IE00BKVL7J92.USD","LU2087621335.USD","IE00BZ1G4Q59.USD","LU2468319806.SGD","LU1559883803.SGD","LU1430594728.SGD","LU0566484027.USD","IE00B3T34201.USD","BK4578","LU1839511570.USD","IE00B19Z3B42.SGD","BK4583","LU2089984988.USD","LU0234570918.USD","LU0320765992.SGD","LU1585245621.USD","BK4139","LU1066053197.SGD","BK4588","CORT","BMRN","BK4585","IE00BSNM7G36.USD","LU1066051498.USD","BK4568"],"gpt_icon":0},{"id":"2518414228","title":"Corcept Therapeutics Initiates Momentum Trial to Determine Prevalence of Hypercortisolism in Patients With Resistant Hypertension","url":"https://stock-news.laohu8.com/highlight/detail?id=2518414228","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518414228?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 20:02","pubTimestamp":1741608130,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nFWN3PT0PJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4532","LU0566484027.USD","CORT","BK4007","LU1559883803.SGD"],"gpt_icon":0},{"id":"2518229575","title":"Corcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension","url":"https://stock-news.laohu8.com/highlight/detail?id=2518229575","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518229575?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 20:00","pubTimestamp":1741608000,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif., March 10, 2025----Corcept Therapeutics Incorporated , a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the initiation of MOMENTUM, a clinical trial examining the prevalence of endogenous hypercortisolism  in patients with resistant hypertension.The MOMENTUM trial, which will enroll 1,000 patients across 45 sites in the U.S., will establish the prevalence of endogenous hypercortisolism in patients with resistant hypertension. Resistant hypertension is defined by the American Heart Association as elevated blood pressure despite the use of three or more antihypertensive medications in different classes, including a diuretic. Patients with a dexamethasone suppression test  value greater than 1.8 g/dL and dexamethasone levels greater than 140 ng/dL will be identified as having hypercortisolism","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/corcept-therapeutics-initiates-momentum-trial-120000275.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0566484027.USD","CORT","BK4532","BK4007","LU1559883803.SGD","DST"],"gpt_icon":0},{"id":"2517681456","title":"Corcept Shares Rise More Than 55% in 6 Months: Here's Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2517681456","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517681456?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 23:56","pubTimestamp":1741362960,"startTime":"0","endTime":"0","summary":"Shares of Corcept Therapeutics Incorporated CORT have rallied 56.4% in the past six months against the industry’s decline of 10.5%.The company’s sole-marketed drug, Korlym , which is approved for treating Cushing's syndrome or endogenous hypercortisolism, has been performing well. The drug has been witnessing strong demand in recent quarters and the trend is likely to continue in 2025.The company’s top line solely comprises product sales from Korlym. Sales of the drug increased almost 40% year over year to $675 million in 2024, owing to strong demand.Corcept is also making good progress with its promising set of pipeline candidates.The company is developing its lead pipeline candidate, relacorilant for treating patients with Cushing’s syndrome. In December 2024, CORT submitted a new drug application  for relacorilant to the FDA for the same.Some other top-ranked stocks in the drug/biotech sector are Organogenesis Holdings Inc ORGO, Jazz Pharmaceuticals plc JAZZ and ANI Pharmaceuticals,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/corcept-shares-rise-more-55-155600800.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","LU0320765992.SGD","LU0889565916.HKD","BK4139","ANIP","LU1559883803.SGD","ORGO","LU0823416689.USD","JAZZ","LU0566484027.USD","LU0109394709.USD","BK4532","CORT","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","BK4533","IE00BN0W2W23.USD"],"gpt_icon":0},{"id":"2517736434","title":"Are Options Traders Betting on a Big Move in Corcept Therapeutics (CORT) Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2517736434","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517736434?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 21:40","pubTimestamp":1741354800,"startTime":"0","endTime":"0","summary":"Investors in Corcept Therapeutics Incorporated CORT need to pay close attention to the stock based on moves in the options market lately. That is because the March 21, 2025 $20 Call had some of the highest implied volatility of all equity options today.Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.Clearly, options traders are pricing in a big move for Corcept Therapeutics shares, but what is the fundamental picture for the company?","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/options-traders-betting-big-move-134000583.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4532","LU1559883803.SGD","LU0566484027.USD","CORT","BK4007"],"gpt_icon":0},{"id":"1157114218","title":"Stock Track | Corcept Therapeutics Plummets 5.03% as Full-Year and Q4 Earnings Disappoint","url":"https://stock-news.laohu8.com/highlight/detail?id=1157114218","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157114218?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 04:52","pubTimestamp":1741121558,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics  stock plunged 5.03% in the intraday session on Tuesday, following the company's disappointing financial results for the full year 2024 and the fourth quarter.For the full year 2024, Corcept reported revenue of $675.0 million, missing analyst estimates by 2.6%. Moreover, the company's earnings per share  of $1.35 fell short of analyst expectations by 13%, further exacerbating investor concerns.The company's fourth-quarter performance was also lackluster, with revenue and EPS","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Stock Track | Corcept Therapeutics Plummets 5.03% as Full-Year and Q4 Earnings Disappoint","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["CORT"],"gpt_icon":0},{"id":"2516675399","title":"Truist Financial Keeps Their Buy Rating on Corcept Therapeutics (CORT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2516675399","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516675399?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 20:38","pubTimestamp":1741091899,"startTime":"0","endTime":"0","summary":"Truist Financial analyst Joon Lee maintained a Buy rating on Corcept Therapeutics (CORT – Research Report) today. The company’s shares closed yeste...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/truist-financial-keeps-their-buy-rating-on-corcept-therapeutics-cort-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/truist-financial-keeps-their-buy-rating-on-corcept-therapeutics-cort-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CORT"],"gpt_icon":0},{"id":"2516783396","title":"Corcept Therapeutics: Strong Buy Rating Driven by NDA Acceptance and Promising Trial Outcomes","url":"https://stock-news.laohu8.com/highlight/detail?id=2516783396","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516783396?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 19:56","pubTimestamp":1741089379,"startTime":"0","endTime":"0","summary":"Analyst Edward Nash of Canaccord Genuity maintained a Buy rating on Corcept Therapeutics (CORT – Research Report), retaining the price target of $1...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/corcept-therapeutics-strong-buy-rating-driven-by-nda-acceptance-and-promising-trial-outcomes?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/corcept-therapeutics-strong-buy-rating-driven-by-nda-acceptance-and-promising-trial-outcomes?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CORT"],"gpt_icon":0},{"id":"2516488620","title":"Corcept Therapeutics Full Year 2024 Earnings: Misses Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2516488620","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516488620?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 19:30","pubTimestamp":1741087826,"startTime":"0","endTime":"0","summary":"Profit margin: 21% . The decrease in margin was driven by higher expenses.NasdaqCM:CORT Revenue and Expenses Breakdown March 4th 2025. All figures shown in the chart above are for the trailing 12 month  period. Revenue missed analyst estimates by 2.6%. Earnings per share  also missed analyst estimates by 13%.In the last 12 months, the only revenue segment was Discovery, Development and Commercialization of Pharmaceutical Products contributing US$675.0m. The largest operating expense was General & Administrative costs, amounting to US$280.3m . Over the last 12 months, the company's earnings were enhanced by non-operating gains of US$2.78m. Explore how CORT's revenue and expenses shape its earnings.Looking ahead, revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 8.5% growth forecast for the Pharmaceuticals industry in the US.The company's shares are down 4.4% from a week ago.Just as investors must consider earnings, it is also important to take into a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/corcept-therapeutics-full-2024-earnings-113026953.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CORT"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.corcept.com","stockEarnings":[{"period":"1week","weight":-0.0687},{"period":"1month","weight":-0.1379},{"period":"3month","weight":0.0412},{"period":"6month","weight":0.2436},{"period":"1year","weight":1.1687},{"period":"ytd","weight":0.0841}],"compareEarnings":[{"period":"1week","weight":-0.0148},{"period":"1month","weight":-0.0654},{"period":"3month","weight":-0.0661},{"period":"6month","weight":-0.0277},{"period":"1year","weight":0.0623},{"period":"ytd","weight":-0.0519}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.52381,"avgChangeRate":0.016463},{"month":2,"riseRate":0.428571,"avgChangeRate":0.014054},{"month":3,"riseRate":0.714286,"avgChangeRate":0.094445},{"month":4,"riseRate":0.55,"avgChangeRate":0.017063},{"month":5,"riseRate":0.47619,"avgChangeRate":0.003602},{"month":6,"riseRate":0.47619,"avgChangeRate":0.043515},{"month":7,"riseRate":0.47619,"avgChangeRate":-0.002799},{"month":8,"riseRate":0.380952,"avgChangeRate":-0.00839},{"month":9,"riseRate":0.428571,"avgChangeRate":0.05599},{"month":10,"riseRate":0.52381,"avgChangeRate":-0.000542},{"month":11,"riseRate":0.47619,"avgChangeRate":0.015887},{"month":12,"riseRate":0.428571,"avgChangeRate":0.055504}],"exchange":"NASDAQ","name":"Corcept Therapeutics","nameEN":"Corcept Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Corcept Therapeutics(CORT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Corcept Therapeutics(CORT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Corcept Therapeutics,CORT,Corcept Therapeutics股票,Corcept Therapeutics股票老虎,Corcept Therapeutics股票老虎国际,Corcept Therapeutics行情,Corcept Therapeutics股票行情,Corcept Therapeutics股价,Corcept Therapeutics股市,Corcept Therapeutics股票价格,Corcept Therapeutics股票交易,Corcept Therapeutics股票购买,Corcept Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Corcept Therapeutics(CORT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Corcept Therapeutics(CORT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction